Last reviewed · How we verify

NCT04919655: CELSR1

Primary Lymphedema and Mutation CELSR1 (Cadherin EGF LAG Seven-pass G-type Receptor 1)

Status unknown Last updated 9 June 2021
What this trial tests

trial in Primary Lymphedema in 31 participants. Status unknown.

Timeline
1 February 2021
Primary endpoint
1 February 2022
20 February 2022

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment31
Start date1 February 2021
Primary completion1 February 2022
Estimated completion20 February 2022
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Eligibility, any sex, with Primary Lymphedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will describe the expression of mutation CELSR1 with codon stop and amino acids substitution mechanism in primary lymphedema, in both clinical examination and imaging exploration

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04919655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing